Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2018

View Archived Issues

FDA expands approval of Gilotrif in NSCLC

SAAP-148 shows promise for combating multidrug-resistant bacteria

Prolong Pharmaceuticals gives update on ongoing projects

FDA approves of Trisenox injection for first-line treatment of acute promyelocytic leukemia

Eurocine Vaccines cleared to begin study of Immunose Flu

InflaRx presents company and pipeline overview

Nanoparticle-encapsulated rapamycin induces immune tolerance to restore immunotoxin activity

FDA grants orphan drug designation to BB-301 for oculopharyngeal muscular dystrophy

FDA accepts Sandoz's BLA for adalimumab biosimilar

LIDDS raises capital through direct share issue

Suzhou Kintor Pharmaceuticals patents mTOR and/or PI3K inhibitors

Japanese approval sought for Opdivo with Yervoy for unresectable or metastatic renal cell carcinoma

Aprinoia Therapeutics completes series B financing round

ValiRx reports phase II data on VAL-401 in late-stage NSCLC

Universite Jagellonne and Neurolixis divulge 5-HT1A receptor agonists

Janssen identifies novel TLR7 and/or TLR8 agonists

Y-mAbs commences phase III study of naxitamab in neuroblastoma with osteomedullary disease

LifeArc presents novel antivirals for HFMD

Novel HLA-G-targeting antibodies presented by Invectys

NHLBI initiates phase I study of HERV-E TCR transduced autologous T cells in renal cell carcinoma

MedImmune studies MEDI-5884 in stable coronary heart disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...